TNF and Cowden disease: Among them, the monoclonal antibody Infliximab (IFX), known as Remicade (Janssen Biotech, Horsham, PA, USA), deserves particular attention, being the first biological response modifier approved by the US Food and Drug Administration (FDA) for the treatment of CD in 1998 and thereby becoming the first inhibitor of TNF employed in the clinical practice9.